Fresenius Medical Care (NYSE:FMS; ETR:FRE) today announced an investment in BioIntelliSense for an undisclosed amount.
Denver-based BioIntelliSense is developing a medical-grade data services platform for continuous remote health monitoring, predictive analytics and algorithmic clinical insights.
Through the agreement, Fresenius will use the advanced analytics and artificial intelligence to develop medical wearables for clinical pathways that allow clinicians to be alerted for early intervention of medical conditions. The company says the combination of the two technologies can help prevent complications and reduce unnecessary and costly hospitalizations.
Fresenius earlier this month expanded into clinical research activities into kidney research.